ArticleBMC microbiology2026
Identification and antifungal susceptibility pattern of Candida species isolated from a tertiary hospital in Irrua, Edo State, Nigeria.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCandida species is a genus of yeast that can be commensals or pathogenic, causing invasive fungal infections that could lead to morbidity and mortality. This study aimed to determine the identity, prevalence and antifungal susceptibility pattern of Candida species isolated from clinical samples of patients attending a tertiary Hospital in Irrua, Edo State, Nigeria.
methodsA total of 286 yeast isolates were recovered from clinical samples of patients sent to the Medical Microbiology Laboratory of Irrua Specialist Teaching Hospital (ISTH), Irrua, Edo State, Nigeria. Identification of yeast isolates and antifungal susceptibility testing (AST) of the isolates to different antifungal agents were assayed using VITEK-2 Compact System (Biomerieux, France).
resultsA total of 286 yeast isolates which included 283 Candida isolates identified into six (6) Candida species (Candida albicans, Candida tropicalis, Nakaseomyces glabrata, Candida parapsilosis, Pichia kudriavzevii (formally Candida krusei) and Candida ciferrii, and 2 non-candida yeast (Papiliotrema laurentii formally Cryptoccocus laurentii and Trichosporon asahii) were recovered. The prevalence of Candida species in this study was 21.7%, while that of yeast infection was 21.9%. Candida albicans was the most frequently isolated species, accounting for 69.6% of isolates while Candida ciferrii was the least isolated (0.3%). Urine specimens had the highest yield of yeast isolates (43.4%), followed by Endocervical swab (24.8%), while blood had the lowest yield (0.7%). Females had higher prevalence of yeast infection than the males (91.6% vs. 8.4%, p < 0.001). Although poor susceptibility was shown to flucytosine (44.9%) and fluconazole (57.9%), the most active antifungal agents were voriconazole (92.2%) and caspofungin (93.2%).
conclusionThere is an urgent need for regional and national surveillance of yeasts of medical importance. To aid effective diagnosis and treatment, culture and AST though expensive is strongly encouraged in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.